


//
//
//

()

*



$5-7 \times 10 L/m^2$

CCI

$10 \times 10 L/m^2$



HLA

()

()

HLA

* /L

(%) HLA

%

(%) %

* /L

()

*

%

$\times \left(\frac{\quad}{10^{11} \times} \right) = \text{CCI}$

$10^{11} \times$

HLA-DR

* /L

CCI

* /L

HLA

%

()

:

HLA

/ /

/ /

/

)

)

(

(

(

)

()	()
-----	-----

CCI

/

/

()

•

()

(%)

:

•

(/)

(/)

%

(/)

()

ALL

:

•

(/)

(%)

AML

)

(/)

()

•

(/)

()

(

P < /

/ ± /

/ ± /

•

/ ± /

/ ± /

•

:

•

)

(

/

•

/

•

(%)

(P < /

P < /

)

(% /)

/

()

%

%

.()

% /

%

()

% /

REFERENCES

2. Barz D, Staack D, Lehmann R, Stange K, Schnurstein K. Antibody formation after filtered blood cell replacement in hematologic-oncologic patients. *Beitr Infusionsther Transfusionsmed* 1996; 33: 30-4.
3. Balducci L, Benson K, Lyman GH, Sanderson R, Fields K, Ballester OF, et al. Cost-effectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia. *Transfusion* 1993; 33(8): 665-70.
4. Hoffman R. *Hematology: Basic principles and practice*. USA: Churchill Livingstone, 1991.
5. Sniecinski I, O'Donnell MR, Nowicki B, Hill LR. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. *Blood* 1988; 71(5): 1402-7.